ISCTM
International Society for CNS Clinical Trials and Methodology

Orphan Diseases Working Group

Chair:
Joan Busner, PhD
Gahan Pandina, PhD, Co-Chair

ISCTM Winter Conference 21 Feb 2024 ▪ Washington, DC

Disclosures

Joan Busner: Full time employee, Signant Health

Gahan Pandina: Full time employee of Janssen Research & Development, LLC; Johnson & Johnson Stockholder

Welcome!

Introductions

Three Orphan Disease Working Group Publications in 2023 (links on ISCTM website)

- Patient Centricity: Design and Conduct of Clinical Trials in Orphan Diseases: Third of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development
- Joan Busner, Gahan Pandina, Simon Day, Atul Mahableshwarkar, Lucas Kempf, Maria Sheean, Judith Dunn
- *Innovations in Clinical Neuroscience, 2023;20(1-3): 25-31*
- **Click here to view full publication**
- Implications of Pediatric Initiatives on CNS Drug Development for All Ages—2020 and Beyond: Second of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development
- Gahan Pandina, Joan Busner, Joseph P. Horrigan, Christine McSherry, Alison Bateman-House, Luca Pani, Judith Kando
- *Innovations in Clinical Neuroscience, 2023;20(1-3): 18-24*
- **Click here to view full publication**
- Special Challenges in Pediatric Drug Development: First of Three Sets of Expanded Proceedings from the ISCTM Autumn Conference on Pediatric Drug Development
- Philip D. Harvey, Joan Busner, Gahan Pandina, H. Gerry Taylor, Meg Grabb, Joohi Jimenez-Shahed
- *Innovations in Clinical Neuroscience, 2023; 20(1-3): 13-17*
- **Click here to view full publication**

2024 – Already Have 1 Orphan Disease Working Group Manuscript in Press

- Just learned that our latest manuscript was accepted for publication, slated for Jan-Feb 2024 issue of Innovations in Clinical Neuroscience
- Title: Ensuring stakeholder feedback in the design and conduct of clinical trials for rare diseases: Position Paper of the ISCTM Orphan Disease Working Group
  Innovations in Clinical Neuroscience
- Authors: Gahan Pandina, Joan Busner, Lucas Kempf, Joan Fallon, Larry Alphs, Maria Acosta, Anna-Karin Berger, Simon Day, Judy Dunn, Victoria Villalta-Gil, Margaret Grabb, Joe Horrigan, William Jacobson, Judy Kando, Tom Macek, Manpreet Singh, Arielle Stanford, Silvia Zaragoza

- Congratulations to all involved – represents another major accomplishment for our WG

Areas for Discussion (1/2): Papers? Subgroups? Sessions?

From meeting in Barcelona:

- Composite approaches to analyses for rare disease trials
  - Multidomain Response Index (MDRI) and composite endpoints (Horrigan)
- How close are we to finding surrogate markers in CNS rare diseases (Potter, Macek, Horrigan, Alphs)?
- How to conceptualize timeframe for changed biomarkers in future (Farmer)
- Accessing large databases to help derive meaningful biomarkers in rare disease trials (Alphs)

Extending thinking for surrogate markers / biomarkers…

- Use of biomarkers to facilitate rare disease endpoint development / validation
  - Actigraphy and other sensor-based technologies for tremor, motor skills, sleep, etc.
  - Geolocation and phone (example: mindLAMP being used in schizophrenia
  - Radar-based motion technologies for gait disturbance/detection
  - Automated video analysis, facial affect, voice, etc. as proxy measures of behavior

Areas for Discussion (2/2): Papers? Subgroups? Sessions?

- Cognition to measure improvement vs. safety impact (Kando)
  - Monika Vance to describe experience with validation of use of cognitive endpoints across the lifespan
- Person ability scores – within-person change – vs norm based scores
  - Cristan Farmer
- Disease modifying therapy in rare disease trials
  - Manpreet Singh
- CGI in CNS rare disease trials – why all the confusion?
  - Jim Youakim
  - Joan Busner